Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008].. Additionally we are shipping LY9 Proteins (16) and LY9 Kits (8) and many more products for this protein.
Showing 10 out of 131 products:
Mouse (Murine) Monoclonal LY9 Primary Antibody for FACS - ABIN2663193
Graham, Bell, McCausland, Huntoon, van Deursen, Faubion, Crotty, McKean: Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice. in Journal of immunology (Baltimore, Md. : 1950) 2005
Show all 5 references for 2663193
Mouse (Murine) Monoclonal LY9 Primary Antibody for FACS, IF - ABIN2660997
Martín, Del Valle, Saborit, Engel: Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229. in Journal of immunology (Baltimore, Md. : 1950) 2005
Show all 5 references for 2660997
Human Monoclonal LY9 Primary Antibody for FACS, ICFC - ABIN2663194
Romero, Zapater, Calvo, Kalko, de la Fuente, Tovar, Ockeloen, Pizcueta, Engel: CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. in Journal of immunology (Baltimore, Md. : 1950) 2005
Show all 5 references for 2663194
Human Monoclonal LY9 Primary Antibody for FACS - ABIN119625
Abazov, Abbott, Abolins, Acharya, Adams, Adams, Agelou, Agram, Ahn, Ahsan, Alexeev, Alkhazov, Alton, Alverson, Alves, Anastasoaie, Andeen, Anderson, Andrieu, Anzelc, Arnoud, Arov, Askew, Asman, Jesus, Atramentov, Autermann, Avila, Ay, Badaud, Baden, Bagby: Measurement of the Bs(0) lifetime using semileptonic decays. in Physical review letters 2007
Show all 3 references for 119625
Human Polyclonal LY9 Primary Antibody for EIA, WB - ABIN783456
Del Valle, Engel, Martín: The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). in The Journal of biological chemistry 2003
Show all 3 references for 783456
Human Monoclonal LY9 Primary Antibody for FACS - ABIN119623
de la Fuente, Tovar, Villamor, Zapater, Pizcueta, Campo, Bosch, Engel: Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. in Blood 2001
Show all 2 references for 119623
Human Monoclonal LY9 Primary Antibody for FACS - ABIN4897608
Atanackovic, Panse, Hildebrandt, Jadczak, Kobold, Cao, Templin, Meyer, Reinhard, Bartels, Lajmi, Zander, Marx, Bokemeyer, Kröger: Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. in Haematologica 2011
the results presented here suggest that the tumor suppressor potential of SLAMF3 occurs through activation of Retinoblastoma protein that represses PLK1 (show PLK1 Antibodies).
study showed CD229 is overexpressed on the malignant plasma cells of patients across all types of plasma cell dyscrasias including multiple myeloma; CD229 is also expressed on the surface of a fraction of cells carrying the phenotype of chemotherapy-resistant and myeloma-propagating cells within the patients' bone marrow
the Val602 variant of the non-synonymous single nucleotide polymorphism (SNP) rs509749 in the SLAM (show SLAMF1 Antibodies) family member CD229 (Ly9, SLAMF3) has a two-fold lower affinity compared with the SLE-associated Met602 variant for the small adaptor protein SAP (show APCS Antibodies)
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Results revealed that SLAMF3 plays a role during hepatitis C virus entry, likely by enhancing entry of viral particle within hepatocytes.
SLAMF3 is an inhibitor of hepatocellular carcinoma cell proliferation and tumor progression.
These results suggest a role for CD319 (show SLAMF7 Antibodies) and CD229 in the systemic lupus erythematosus disease process.
Data indicate that the dominance of the SLAMF3/SLAMF6 (show SLAMF6 Antibodies) pathway in inducing IL-17A (show IL17A Antibodies) production can be attributed to an increased nuclear abundance and recruitment of RORgammat to the IL17A (show IL17A Antibodies) promoter.
SLAMF3 and SLAMF6 (show SLAMF6 Antibodies) T cell surface expression and IL-17 (show IL17A Antibodies) levels significantly correlate with disease activity in systemic lupus erythematosus patients
CD229 is specifically over-expressed on myeloma cells including their clonogenic precursors and contributes to their malignant phenotype.
Ly9/CD229 cell surface receptor emerges as a uniquely important element for modulating innate T cell function, acting as an inhibitory molecule that regulates invariant natural killer (NK)T cell development and innate-like CD8 (show CD8A Antibodies) T cell expansion.
Data show that defective tolerance was observed only in Fcgr2b (show FCGR2B Antibodies)-deficient mice with autoimmune-type Slam (show SLAMF1 Antibodies) family genes, indicating that epistatic effects of both genes are involved.
mouse novel Ly9 (show SLAMF7 Antibodies) is a new member of the expanding CD150 (show SLAMF1 Antibodies) family of cell surface receptors
CD229 is a self-ligand, interacting through its N-terminal V-like domain which contains three amino acid residues critical for the homophilic binding interaction.
CD229 is a pan (show SUPT6H Antibodies)-lymphocyte marker and indicate that mAbs against CD229 are able to down-modulate T-cell activation.
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006
lymphocyte antigen 9
, T-lymphocyte surface antigen Ly-9
, T-lymphocyte surface antigen Ly-9-like
, t-lymphocyte surface antigen Ly-9-like
, SLAM family member 3
, cell surface molecule Ly-9
, signaling lymphocytic activation molecule 3